Cisplatin – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 75 min read

Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

On this page10 sections

Article Summary

Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury. Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other...

Key Takeaways

This article explains Mechanism of action in simple medical language.
This article explains Indications in simple medical language.
This article explains Contraindications in simple medical language.
This article explains Dosage in simple medical language.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.

Educational health guideWritten for patient understanding and clinical awareness.

Reviewed content workflowUse writer and reviewer profiles for stronger trust.

Emergency safety firstUrgent warning signs are highlighted below.

Choose your reading view

Patient View highlights a simple learning journey. Clinical View reveals structure, evidence, and editorial completeness.

Evidence Trust Passport

How this article is supported

87/100

Written byDr. Harun Ar Rashid, MD - Arthritis, Bones, Joints Pain, Trauma, and Internal Medicine Specialist

Medical review1 reviewer

Last reviewedNot scheduled

Next reviewNot scheduled

References1 source entry

Review statusReview schedule needed

Medical library classification Drug monograph Drugs A–Z

This passport makes the article’s review, evidence, and update signals visible. It does not guarantee that every section is complete or replace personal medical advice.

Definition

Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury.

Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have.

Cisplatin, cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result – disruption of DNA function and cell death.

Indications

For the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.
Mantle cell lymphoma that has relapsed (come back) or is refractory (does not respond to treatment).
Precursor B lymphoblastic leukemia (a type of acute lymphoblastic leukemia) has relapsed or is refractory.
Advanced Ovarian Cancer
Ovarian Cancer Metastatic
Advanced Bladder cancer
Advanced Testicular cancer
Metastatic Testicular cancer

Use in Cancer

Cisplatin is approved to be used alone or with other drugs to treat:

Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, such as surgery or radiation therapy.
Ovarian cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy. It is used alone in patients whose cancer has not gotten better with standard chemotherapy and who have not received previous cisplatin.
Testicular cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy.

Cisplatin is also being studied in the treatment of other types of cancer.

Contraindications

are allergic to cisplatin, any platinum-containing compounds, or any ingredients of the medication
have hearing impairment
have reduced bone marrow function (e.g. low white cells)
have reduced kidney function
Severe hypersensitivity to cisplatin or platinum compounds would preclude its administration; cisplatin is contraindicated in patients who have had severe hypersensitivity reactions, and rechallenge is not a recommendation.
Cisplatin has been shown to cross the placenta and may cause fetal harm.[rx][rx] Women of reproductive age should use reliable contraception during treatment and up to a year from the final treatment date.
Cisplatin is also present in the breast milk of lactating women on a cisplatin regimen.[rx] Breastfeeding is not recommended during treatment.[rx] If hypersensitivity occurs, the provider should discontinue cisplatin immediately.[rx]
a bad infection
acute leukemia
low amount of magnesium in the blood
low amount of calcium in the blood
low amount of sodium in the blood
low amount of potassium in the blood
hemolytic uremic syndrome, a condition that affects the kidney and the blood
anemia
decreased blood platelets
low levels of white blood cells
a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
sudden blindness and pain upon moving the eye
ototoxicity, damage to the inner ear that affects hearing or balance
hearing loss
a heart attack
a clot in the lung
a stroke
inflammation of blood vessels in the brain or spinal cord
Raynaud’s phenomenon, a condition where blood vessels constrict too much with coldness or stress
blood clot in a deep vein of the extremities
thrombotic thrombocytopenic purpura, a type of blood disorder
decreased kidney function
vomiting
amount of uric acid in the blood
pregnancy
a patient who is producing milk and breastfeeding
TPMT poor metabolizer
a type of brain disorder called posterior reversible encephalopathy syndrome
a clot in the aorta
kidney disease with likely reduction in kidney function

Dosage

Strengths: 50 mg; 10 mg; 1 mg/mL

Testicular Cancer

20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents

Ovarian Cancer

75 to 100 mg/m2 by slow IV infusion once every 3 to 4 weeks on Day 1

Bladder Cancer

50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended

FDA Approved Adult Dosing Regimens

Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
Advanced bladder cancer: 50 to 70 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
Advanced ovarian cancer: 100 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.

Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring urine output before, during, and for 24 hours following administration.

Renal Dose Adjustments

Creatinine clearance between 10 and 50: decrease dose by 25%
Creatinine clearance below 10: decrease dose by 50%
Hemodialysis: Decrease the dose by 50% with no supplement; administer after dialysis on dialysis days with no supplement
Peritoneal dialysis: Decrease the dose by 50% with no supplement

Side Effects

The Most Common

nausea
vomiting
diarrhea
hair loss
loss in ability to taste food
hiccups
dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration
swelling, pain, redness, or burning at the injection site
pain, burning, or tingling in the hands or feet
muscle cramps
difficulty walking
feeling of an electric-like shock when you bend your neck forward
seizures
sudden changes in vision, including color vision
loss of vision
eye pain
chest pain or pressure
fever, sore throat, chills, or other signs of infection
unusual bleeding or bruising
black and tarry stools
red blood in stools
bloody vomit
vomited material that looks like coffee grounds

More Common

loss of appetite
nausea and vomiting
taste disturbances
temporary hair loss
blurred vision
diarrhea
difficulty in the ability to distinguish colors
difficulty walking
hearing difficulties
loss of balance
loss of reflexes
muscle cramps
numbness or tingling in fingers or toes
ringing in ears
severe nausea and vomiting
unusual tiredness or weakness
walking problems

Rare

pain, redness, or swelling at the site of injection
seizures
signs of a serious allergic reaction (difficulty breathing, wheezing, swelling of the face and throat, increased heart rate, dizziness)
signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on the skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding)
signs of infection (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness)
pain, burning, redness at the injection site,
numbness, tingling, coldness or blue discoloration of the hands or feet,
pain, redness, swelling of arms or legs,
loss of reflexes,
loss of balanced,
trouble walking,
muscle cramps or spasms,
weakness,
neck or back pain,
mouth or tongue sores,
joint pain,

Drug Interaction

DRUG	INTERACTION
Abacavir	Abacavir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Abatacept	The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Cisplatin.
Acebutolol	Cisplatin may increase the bradycardic activities of Acebutolol.
Aceclofenac	Aceclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Acemetacin	Acemetacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cisplatin.
Acetaminophen	Acetaminophen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Acetazolamide	Acetazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Acetylcholine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Acetylcholine.
Acetyldigitoxin	Acetyldigitoxin may decrease the cardiotoxic activities of Cisplatin.
Acetylsalicylic acid	Acetylsalicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Aclidinium	Aclidinium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Acrivastine	Acrivastine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Acyclovir	Acyclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin.
Adefovir dipivoxil	Adefovir dipivoxil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Adenovirus	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cisplatin.
Albutrepenonacog alfa	Albutrepenonacog alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Alclofenac	Alclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin.
Alendronic acid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid.
Allogeneic processed	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Cisplatin.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Cisplatin.
Almasilate	Almasilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Almotriptan	Almotriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Alogliptin	Alogliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Alprazolam	Alprazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Cisplatin.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin.
Amantadine	The serum concentration of Cisplatin can be increased when it is combined with Amantadine.
Amifampridine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Amifampridine.
Amikacin	Amikacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amiloride	The serum concentration of Cisplatin can be increased when it is combined with Amiloride.
Aminohippuric acid	The serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid.
Aminophenazone	Aminophenazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amiodarone	The serum concentration of Cisplatin can be increased when it is combined with Amiodarone.
Amitriptyline	Amitriptyline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ammonium chloride	Ammonium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amobarbital	The therapeutic efficacy of Amobarbital can be decreased when used in combination with Cisplatin.
Amoxapine	The therapeutic efficacy of Amoxapine can be decreased when used in combination with Cisplatin.
Amoxicillin	Amoxicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amphetamine	Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amphotericin B	Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ampicillin	Ampicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amrinone	Amrinone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Cisplatin.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Cisplatin.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin.
Anastrozole	The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Anastrozole.
Ancestim	Ancestim may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Cisplatin.
Anifrolumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Anifrolumab.

Belatacept	The risk or severity of adverse effects can be increased when Cisplatin is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat.
Belladonna	The therapeutic efficacy of Belladonna can be decreased when used in combination with Cisplatin.
Belumosudil	The risk or severity of adverse effects can be increased when Cisplatin is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Cisplatin.
Bendamustine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine.
Bendroflumethiazide	Bendroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Benorilate	Benorilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benoxaprofen	Benoxaprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benserazide	Benserazide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benzatropine	Benzatropine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benznidazole	Benznidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzocaine.
Benzonatate	Cisplatin may increase the neuromuscular blocking activities of Benzonatate.
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Cisplatin.
Benzthiazide	Benzthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Benzydamine	Benzydamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzyl alcohol.
Bepotastine	Bepotastine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Betamethasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone.
Betamethasone phosphate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone phosphate.
Betaxolol	Cisplatin may increase the bradycardic activities of Betaxolol.
Bethanechol	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bethanechol.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Cisplatin.
Bevacizumab	The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin.
Bicisate	Bicisate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bimekizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bimekizumab.
Biperiden	The therapeutic efficacy of Biperiden can be decreased when used in combination with Cisplatin.
Bismuth subgallate	Bismuth subgallate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bisoprolol	Bisoprolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bisoxatin	Bisoxatin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Cisplatin.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin.
Blinatumomab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Blinatumomab.
Bordetella pertussis	The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Cisplatin.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin.
Bosutinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin.
Brivaracetam	Brivaracetam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Brodalumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Brodalumab.
Bromazepam	Bromazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bromotheophylline	Bromotheophylline may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Cisplatin.
Buclizine	The therapeutic efficacy of Buclizine can be decreased when used in combination with Cisplatin.
Budesonide	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Budesonide.
Bumadizone	Bumadizone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Bumetanide	The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Bupivacaine.
Bupropion	The excretion of Cisplatin can be decreased when combined with Bupropion.
Buspirone	Buspirone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Busulfan	The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan.
Butabarbital	Butabarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Butacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butacaine.
Butalbital	The therapeutic efficacy of Butalbital can be decreased when used in combination with Cisplatin.
Butamben	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butamben.
Butobarbital	The therapeutic efficacy of Butobarbital can be decreased when used in combination with Cisplatin.
Butylscopolamine	The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Cisplatin.
Cabazitaxel	The risk or severity of adverse effects can be increased when Cisplatin is combined with Cabazitaxel.
Canagliflozin	Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Canakinumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Cisplatin.
Canrenoic acid	Canrenoic acid may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Capecitabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin.
Capreomycin	Capreomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Capsaicin.
Carbamazepine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamazepine.
Carbamoylcholine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine.
Carbidopa	Carbidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Carboplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin.
Carfilzomib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin.
Carprofen	Carprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Carvedilol	Cisplatin may increase the bradycardic activities of Carvedilol.
Cefaclor	Cefaclor may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefadroxil	Cefadroxil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefalotin	Cefalotin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefamandole	Cefamandole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefapirin	Cefapirin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefazolin	Cefazolin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefdinir	Cefdinir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefditoren	Cefditoren may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefepime	Cefepime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefmenoxime	Cefmenoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefmetazole	Cefmetazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefonicid	Cefonicid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefoperazone	Cefoperazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceforanide	Ceforanide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefotaxime	Cefotaxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefotetan	Cefotetan may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefotiam	Cefotiam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefoxitin	Cefoxitin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefpiramide	Cefpiramide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefpirome	Cefpirome may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefpodoxime	Cefpodoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefprozil	Cefprozil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefradine	Cefradine may decrease the excretion rate of Cisplatin which could result in a higher serum level.

Ceftazidime	Ceftazidime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceftibuten	Ceftibuten may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceftizoxime	Ceftizoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceftobiprole	Ceftobiprole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceftolozane	Ceftolozane may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ceftriaxone	Ceftriaxone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cefuroxime	Cefuroxime may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Celecoxib	Celecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Celiprolol	Cisplatin may increase the bradycardic activities of Celiprolol.
Cenobamate	The metabolism of Cenobamate can be decreased when combined with Cisplatin.
Cephalexin	Cephalexin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cephaloglycin	Cephaloglycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Cisplatin is combined with Certolizumab pegol.
Cetirizine	Cetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cevimeline	Cevimeline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chloral hydrate	Chloral hydrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cisplatin.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cisplatin.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Chloroprocaine.
Chloroquine	Chloroquine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chlorothiazide	Chlorothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Chloroxylenol	Chloroxylenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chlorpheniramine	The serum concentration of Cisplatin can be increased when it is combined with Chlorpheniramine.
Chlorpromazine	Chlorpromazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chlorpropamide	Chlorpropamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chlorprothixene	The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Cisplatin.
Chlorthalidone	Chlorthalidone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Chlorzoxazone	Chlorzoxazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Choline	The serum concentration of Cisplatin can be increased when it is combined with Choline.
Choline C 11	Choline C 11 may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Choline magnesium	Choline magnesium trisalicylate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Choline salicylate	The serum concentration of Cisplatin can be increased when it is combined with Choline salicylate.
Chondroitin sulfate	Chondroitin sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromic chloride	Chromic chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromic nitrate	Chromic nitrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromium	Chromium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromium gluconate	Chromium gluconate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromium nicotinate	Chromium nicotinate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Chromous sulfate	Chromous sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ciclesonide	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Ciclesonide.
Cidofovir	Cidofovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cilostazol	Cilostazol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cimetidine	The serum concentration of Cisplatin can be increased when it is combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cinchocaine.
Cinnarizine	The metabolism of Cinnarizine can be decreased when combined with Cisplatin.
Ciprofloxacin	Ciprofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Cisapride	The metabolism of Cisapride can be decreased when combined with Cisplatin.
Cisatracurium	The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Cisplatin.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Cisplatin.
Clevidipine	Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clidinium	The therapeutic efficacy of Clidinium can be decreased when used in combination with Cisplatin.
Clobazam	Clobazam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clobetasol propionate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Clobetasol propionate.
Clodronic acid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Clodronic acid.
Clofarabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine.
Clomipramine	Clomipramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clonazepam	Clonazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clopidogrel	The serum concentration of Cisplatin can be increased when it is combined with Clopidogrel.
Clorazepic acid	Clorazepic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clostridium	The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin.
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Cisplatin.
Clove oil	Clove oil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Clozapine	The risk or severity of neutropenia can be increased when Cisplatin is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cocaine.
Colchicine	Colchicine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Colistimethate	Colistimethate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Colistin	Cisplatin may decrease the excretion rate of Colistin which could result in a higher serum level.
Conivaptan	Conivaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Conjugated	Conjugated estrogens may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Corifollitropin alfa	Corifollitropin alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Corticotropin	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Corticotropin.
Cortisone acetate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cortisone acetate.
Corynebacterium	The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin.
Crizotinib	The serum concentration of Cisplatin can be increased when it is combined with Crizotinib.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin.
Cyclopenthiazide	Cyclopenthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin.
Cyclosporine	Cisplatin may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	Cyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Cycrimine	The therapeutic efficacy of Cycrimine can be decreased when used in combination with Cisplatin.
Cyproheptadine	The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Cisplatin.
Cytarabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Cisplatin.
Dabigatran etexilate	Dabigatran etexilate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dabrafenib	The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib.
Dacarbazine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine.
Dactinomycin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin.
Dalfampridine	The serum concentration of Dalfampridine can be increased when it is combined with Cisplatin.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Cisplatin.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Cisplatin.
Dapagliflozin	Dapagliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Daptomycin	Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin.
Darifenacin	The therapeutic efficacy of Darifenacin can be decreased when used in combination with Cisplatin.
Dasatinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib.
Daunorubicin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.
Decitabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine.
Deferiprone	Deferiprone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Cisplatin.

Deflazacort	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Deflazacort.
Delafloxacin	Delafloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.
Desipramine	The serum concentration of Cisplatin can be increased when it is combined with Desipramine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Cisplatin.
Deslanoside	Deslanoside may decrease the cardiotoxic activities of Cisplatin.
Desloratadine	The therapeutic efficacy of Desloratadine can be decreased when used in combination with Cisplatin.
Desmopressin	Desmopressin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Desoximetasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Desoximetasone.
Desvenlafaxine	Desvenlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Deucravacitinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Deucravacitinib.
Deutetrabenazine	Deutetrabenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dexamethasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone.
Dexamethasone acetate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone acetate.
Dexchlorpheniramine	The serum concentration of Cisplatin can be increased when it is combined with Dexchlorpheniramine maleate.
Dexibuprofen	Dexibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dexketoprofen	Dexketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dexmedetomidine	Dexmedetomidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dexpanthenol	Dexpanthenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin.
Dextran	Dextran may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dextromethorphan	The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Cisplatin.
Diatrizoate	Diatrizoate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diazepam	Diazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dichlorobenzyl alcohol	Dichlorobenzyl alcohol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diclofenac	Diclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diclofenamide	Diclofenamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Cisplatin.
Dicyclomine	Dicyclomine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Didanosine	Didanosine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dienogest	Dienogest may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Diflunisal	Diflunisal may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Difluocortolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Difluocortolone.
Digitoxin	Digitoxin may decrease the cardiotoxic activities of Cisplatin.
Digoxin	Cisplatin may decrease the excretion rate of Digoxin which could result in a higher serum level.
Dihydrostreptomycin	Dihydrostreptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dimercaprol	Dimercaprol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dimethyl fumarate.
Dimethyl sulfoxide	Dimethyl sulfoxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dimetindene	The therapeutic efficacy of Dimetindene can be decreased when used in combination with Cisplatin.
Dinoprostone	The serum concentration of Cisplatin can be increased when it is combined with Dinoprostone.
Dinutuximab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Dinutuximab.
Diphemanil	The therapeutic efficacy of Diphemanil can be decreased when used in combination with Cisplatin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Diphenhydramine.
Diphenidol	The therapeutic efficacy of Diphenidol can be decreased when used in combination with Cisplatin.
Dipyridamole	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Cisplatin is combined with Diroximel fumarate.
Disopyramide	The serum concentration of Cisplatin can be increased when it is combined with Disopyramide.
DL-Methylephedrine	DL-Methylephedrine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dobutamine	Dobutamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Docetaxel	The risk or severity of adverse effects can be increased when Cisplatin is combined with Docetaxel.
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Cisplatin.
Dolutegravir	The serum concentration of Cisplatin can be increased when it is combined with Dolutegravir.
Domperidone	The metabolism of Domperidone can be decreased when combined with Cisplatin.
Dopamine	The serum concentration of Cisplatin can be increased when it is combined with Dopamine.
Doripenem	Doripenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dosulepin	The metabolism of Dosulepin can be decreased when combined with Cisplatin.
Doxacurium	Doxacurium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Doxepin	Doxepin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Doxorubicin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Doxorubicin.
Doxycycline	Doxycycline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Doxylamine	The therapeutic efficacy of Doxylamine can be decreased when used in combination with Cisplatin.
Dronedarone	The serum concentration of Cisplatin can be increased when it is combined with Dronedarone.
Drospirenone	Drospirenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin.
Droxidopa	Droxidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Duloxetine	Duloxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Dyclonine.
Dyphylline	Dyphylline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cisplatin.
Eculizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Cisplatin.
Edoxaban	Edoxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Edrophonium	Edrophonium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin.
Efavirenz	The metabolism of Efavirenz can be decreased when combined with Cisplatin.
Emapalumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab.
Enalaprilat	Enalaprilat may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Cisplatin.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Cisplatin.
Enzalutamide	Enzalutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ephedrine	Cisplatin may increase the neuromuscular blocking activities of Ephedrine.
Epinastine	The metabolism of Epinastine can be decreased when combined with Cisplatin.
Epinephrine	The serum concentration of Cisplatin can be increased when it is combined with Epinephrine.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin.
Eplerenone	Eplerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Epoprostenol	Epoprostenol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin.
Erdafitinib	The serum concentration of Cisplatin can be increased when it is combined with Erdafitinib.
Eribulin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin.
Ertapenem	Ertapenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ertugliflozin	Ertugliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cisplatin.
Escitalopram	The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cisplatin.
Esketamine	The metabolism of Esketamine can be decreased when combined with Cisplatin.
Esmolol	Cisplatin may increase the bradycardic activities of Esmolol.
Estazolam	Estazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Estradiol	The serum concentration of Cisplatin can be increased when it is combined with Estradiol.

Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin.
Ethambutol	Ethambutol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Etidocaine.
Etidronic acid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Etidronic acid.
Etodolac	Etodolac may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Etomidate	Etomidate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Etonogestrel	Etonogestrel may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Etoposide	The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide.
Etoricoxib	Etoricoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Eucalyptus oil	Eucalyptus oil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Everolimus	The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus.
Ezogabine	Ezogabine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Famotidine	The serum concentration of Cisplatin can be increased when it is combined with Famotidine.
Fenbufen	Fenbufen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fenfluramine	The metabolism of Fenfluramine can be decreased when combined with Cisplatin.
Fenofibrate	Fenofibrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fenofibric acid	Fenofibric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fenoldopam	Fenoldopam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fenoprofen	Fenoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fenoterol	The therapeutic efficacy of Fenoterol can be decreased when used in combination with Cisplatin.
Fentanyl	Fentanyl may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fesoterodine	Fesoterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fexinidazole	The serum concentration of Cisplatin can be increased when it is combined with Fexinidazole.
Filgotinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Filgotinib.
Finerenone	Finerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Fingolimod	Cisplatin may increase the immunosuppressive activities of Fingolimod.
Flavoxate	Flavoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Floctafenine	Floctafenine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Florbetaben (18F)	Florbetaben (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Florbetapir (18F)	Florbetapir (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Cisplatin.
Fluconazole	Fluconazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Flucytosine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine.
Fludarabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine.
Fludeoxyglucose (18F)	Fludeoxyglucose (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fludrocortisone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fludrocortisone.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Cisplatin.
Flumazenil	Flumazenil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Flumethasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flumethasone.
Flunisolide	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flunisolide.
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Cisplatin.
Fluocinolone acetonide	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinolone acetonide.
Fluocinonide	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinonide.
Fluocortolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocortolone.
Fluorometholone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluorometholone.
Fluorouracil	The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil.
Fluoxetine	The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cisplatin.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cisplatin.
Fluprednisolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluprednisolone.
Flurazepam	The serum concentration of Cisplatin can be increased when it is combined with Flurazepam.
Flurbiprofen	Flurbiprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Flutamide	Flutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fluticasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone.
Fluticasone furoate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone furoate.
Fluticasone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone propionate.
Fluvoxamine	Fluvoxamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Folic acid	Folic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fomepizole	Fomepizole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fondaparinux	Fondaparinux may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Formestane	Formestane may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Foscarnet	The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet.
Fosfomycin	Fosfomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fosinopril	Fosinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Fosphenytoin	Cisplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Framycetin	Framycetin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Furosemide	Furosemide may increase the nephrotoxic and ototoxic activities of Cisplatin.
Gabapentin enacarbil	Gabapentin enacarbil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadobenic acid	Gadobenic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadodiamide	Gadodiamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadofosveset trisodium	Gadofosveset trisodium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadopentetic acid	Gadopentetic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadoteric acid	Gadoteric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gadoteridol	Gadoteridol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gallamine	The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with Cisplatin.
Gallium nitrate	The risk or severity of adverse effects can be increased when Cisplatin is combined with Gallium nitrate.
Ganciclovir	Ganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cisplatin.
Gemfibrozil	Gemfibrozil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin.
Gentamicin	The serum concentration of Gentamicin can be increased when it is combined with Cisplatin.
Gimeracil	Gimeracil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Givosiran	Givosiran may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Glatiramer	The risk or severity of adverse effects can be increased when Cisplatin is combined with Glatiramer.
Glipizide	Glipizide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Glycerol phenylbutyrate	Glycerol phenylbutyrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Glycopyrronium	The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin.
Golimumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Golimumab.
Golodirsen	Golodirsen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Goserelin	Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Grepafloxacin	The serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin.
Guanethidine	Guanethidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.

Haloperidol	Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Halothane	The metabolism of Halothane can be decreased when combined with Cisplatin.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Cisplatin.
Hepatitis A Vaccine	The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cisplatin.
Hepatitis B Vaccine	The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cisplatin.
Hexafluronium	The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Cisplatin.
Hexocyclium	The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Cisplatin.
Histamine	The serum concentration of Cisplatin can be increased when it is combined with Histamine.
Homatropine	The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Cisplatin.
Human adenovirus	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cisplatin.
Hydralazine	Hydralazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Hydrochlorothiazide	Hydrochlorothiazide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Hydrocodone	The metabolism of Hydrocodone can be decreased when combined with Cisplatin.
Hydrocortisone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone.
Hydrocortisone acetate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone acetate.
Hydrocortisone butyrate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone butyrate.
Hydrocortisone cypionate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone cypionate.
Hydrocortisone succinate	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone succinate.
Hydroflumethiazide	Hydroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Hydromorphone	Hydromorphone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Hydroxocobalamin	Hydroxocobalamin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine.
Hydroxyethyl Starch	Hydroxyethyl Starch may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Hydroxyurea	The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxyurea.
Hyoscyamine	The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Cisplatin.
Ibandronate	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin.
Ibrutinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib.
Ibuprofen	Ibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ibutilide	Ibutilide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Icatibant	Icatibant may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Icosapent	Icosapent may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cisplatin.
Idarubicin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin.
Idarucizumab	Idarucizumab may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Idebenone	Idebenone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Idelalisib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib.
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Cisplatin.
Iloprost	The risk or severity of bleeding can be increased when Iloprost is combined with Cisplatin.
Imatinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib.
Imipramine	The serum concentration of Cisplatin can be increased when it is combined with Imipramine.
Indapamide	Indapamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Indigotindisulfonic acid	Indigotindisulfonic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin.
Inebilizumab	The risk or severity of infection can be increased when Cisplatin is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin.

Ketoprofen	Ketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ketorolac	Ketorolac may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Labetalol	Labetalol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lamivudine	Lamivudine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lamotrigine	The serum concentration of Cisplatin can be increased when it is combined with Lamotrigine.
Latamoxef	Latamoxef may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ledipasvir	Ledipasvir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Leflunomide	The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cisplatin.
Lenvatinib	The serum concentration of Cisplatin can be increased when it is combined with Lenvatinib.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.
Lesinurad	Lesinurad may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Leuprolide	Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Levacetylmethadol	The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Cisplatin.
Levobetaxolol	Cisplatin may increase the bradycardic activities of Levobetaxolol.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Levobupivacaine.
Levocarnitine	Levocarnitine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Levocetirizine	Levocetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Levofloxacin	Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Levoketoconazole	The serum concentration of Cisplatin can be increased when it is combined with Levoketoconazole.
Levomilnacipran	Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Levosalbutamol	Levosalbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Lidocaine.
Linagliptin	The serum concentration of Cisplatin can be increased when it is combined with Linagliptin.
Linezolid	The risk or severity of adverse effects can be increased when Cisplatin is combined with Linezolid.
Liothyronine	Liothyronine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lipegfilgrastim	Cisplatin may increase the myelosuppressive activities of Lipegfilgrastim.
Lipoic acid	The risk or severity of cytotoxicity can be decreased when Lipoic acid is combined with Cisplatin.
Lisinopril	Lisinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lithium carbonate	Cisplatin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level.
Lithium citrate	Lithium citrate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lixisenatide	Lixisenatide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lofexidine	Lofexidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lomustine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Lomustine.
Lopinavir	The serum concentration of Cisplatin can be increased when it is combined with Lopinavir.
Loracarbef	Loracarbef may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lorazepam	Lorazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lorcaserin	Lorcaserin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lornoxicam	Lornoxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lorpiprazole	Lorpiprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Loxoprofen	Loxoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lubiprostone	Lubiprostone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Lumiracoxib	Lumiracoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Macitentan	Macitentan may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Cisplatin.
Magnesium carbonate	Magnesium carbonate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Magnesium chloride	Magnesium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Magnesium hydroxide	Magnesium hydroxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Magnesium trisilicate	Magnesium trisilicate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mangafodipir	Mangafodipir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mannitol	The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cisplatin.
Maprotiline	Maprotiline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Measles virus vaccine	The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Cisplatin.
Mebeverine	The therapeutic efficacy of Mebeverine can be decreased when used in combination with Cisplatin.
Mecamylamine	Mecamylamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mechlorethamine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine.
Meclizine	The therapeutic efficacy of Meclizine can be decreased when used in combination with Cisplatin.
Meclofenamic acid	Meclofenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Medroxyprogesterone	Medroxyprogesterone acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mefenamic acid	Mefenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Megestrol acetate	Megestrol acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Cisplatin is combined with Melphalan.
Memantine	Memantine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Meningococcal	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Cisplatin.
Mepenzolate	The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Cisplatin.
Meperidine	Meperidine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Cisplatin.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Mepolizumab.
Meprednisone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine.
Meropenem	Meropenem may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Mesalazine	Mesalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Metamfetamine	Metamfetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Metamizole	Metamizole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Metaxalone	Metaxalone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Methacholine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Methacholine.
Methadone	Methadone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Methantheline	The therapeutic efficacy of Methantheline can be decreased when used in combination with Cisplatin.
Methazolamide	Methazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Methimazole	The risk or severity of adverse effects can be increased when Cisplatin is combined with Methimazole.
Methotrexate	The risk or severity of adverse effects can be increased when Cisplatin is combined with Methotrexate.
Methotrimeprazine	The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Cisplatin.
Methoxsalen	Methoxsalen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Methoxy polyethylene	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin.
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Cisplatin.
Methscopolamine	The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Cisplatin.
Methscopolamine	The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Cisplatin.
Methyldopa	Methyldopa may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Methylene blue	The serum concentration of Cisplatin can be increased when it is combined with Methylene blue.
Methylnaltrexone	Methylnaltrexone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Methylphenobarbital	The metabolism of Methylphenobarbital can be decreased when combined with Cisplatin.
Methylprednisolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone.
Methylprednisolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone aceponate.
Methylprednisolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone hemisuccinate.
Methyltestosterone	Methyltestosterone may decrease the excretion rate of Cisplatin which could result in a higher serum level.


Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin.
Muzolimine	Muzolimine may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolate mofetil.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolic acid.
N-acetyltyrosine	N-acetyltyrosine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nabumetone	Nabumetone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nadolol	Nadolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Cisplatin.
Naldemedine	Naldemedine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nalmefene	Nalmefene may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Naloxone	Naloxone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Naproxen	Naproxen may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Natalizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.
Nateglinide	Nateglinide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nebivolol	Cisplatin may increase the bradycardic activities of Nebivolol.
Nedaplatin	Cisplatin may decrease the excretion rate of Nedaplatin which could result in a higher serum level.
Nedocromil	Nedocromil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nefazodone	Nefazodone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nelarabine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Nelarabine.
Neomycin	The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Neomycin.
Netilmicin	Cisplatin may decrease the excretion rate of Netilmicin which could result in a higher serum level.
Nevirapine	The metabolism of Nevirapine can be decreased when combined with Cisplatin.
Nicardipine	The therapeutic efficacy of Nicardipine can be decreased when used in combination with Cisplatin.
Nicorandil	Nicorandil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nicotine	The serum concentration of Cisplatin can be increased when it is combined with Nicotine.
Nifedipine	Nifedipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nilotinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Nilotinib.
Nilutamide	Nilutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nimesulide	Nimesulide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nisoldipine	Nisoldipine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nitric Oxide	Nitric Oxide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nitrofurantoin	Nitrofurantoin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Nitroprusside	Nitroprusside may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Norepinephrine	The serum concentration of Cisplatin can be increased when it is combined with Norepinephrine.
Norgestimate	The metabolism of Norgestimate can be decreased when combined with Cisplatin.
Nortriptyline	The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Cisplatin.
Nuvaxovid	The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Cisplatin.
Obinutuzumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Cisplatin.
Octinoxate	Octinoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ofatumumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ofatumumab.
Olanzapine	The therapeutic efficacy of Olanzapine can be decreased when used in combination with Cisplatin.
Olaparib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib.
Olsalazine	Olsalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Opium	Opium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Orphenadrine	The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Cisplatin.
Oseltamivir	Oseltamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Osilodrostat	The metabolism of Osilodrostat can be decreased when combined with Cisplatin.
Ospemifene	The metabolism of Ospemifene can be decreased when combined with Cisplatin.
Ouabain	Ouabain may decrease the cardiotoxic activities of Cisplatin.
Oxacillin	Oxacillin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Oxaliplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Oxaliplatin.
Oxaprozin	Oxaprozin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Oxazepam	Oxazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxetacaine.
Oxprenolol	The serum concentration of Cisplatin can be increased when it is combined with Oxprenolol.
Oxybenzone	Oxybenzone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxybuprocaine.
Oxybutynin	The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Cisplatin.
Oxyphenbutazone	Oxyphenbutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Oxyphencyclimine	The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Cisplatin.
Oxyphenonium	The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Cisplatin.
Oxyquinoline	Oxyquinoline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ozanimod	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel.
Palbociclib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin.
Paliperidone	Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Palonosetron	Palonosetron may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Pamidronic acid	Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Pancuronium	The therapeutic efficacy of Pancuronium can be decreased when used in combination with Cisplatin.
Panobinostat	The risk or severity of adverse effects can be increased when Cisplatin is combined with Panobinostat.
Pantoprazole	Pantoprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.

Ranitidine	The serum concentration of Cisplatin can be increased when it is combined with Ranitidine.
Ranolazine	The serum concentration of Cisplatin can be increased when it is combined with Ranolazine.
Rapacuronium	The therapeutic efficacy of Rapacuronium can be decreased when used in combination with Cisplatin.
Rasagiline	Rasagiline may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ravulizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ravulizumab.
Reserpine	Reserpine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Resorcinol	Resorcinol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin.
Revefenacin	The therapeutic efficacy of Revefenacin can be decreased when used in combination with Cisplatin.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Cisplatin.
Ribavirin	Ribavirin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Ribostamycin	Cisplatin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.
Rilonacept	The risk or severity of adverse effects can be increased when Cisplatin is combined with Rilonacept.
Risankizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Risankizumab.
Risedronic acid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Risedronic acid.
Rituximab	Rituximab may increase the nephrotoxic activities of Cisplatin.
Rivaroxaban	Rivaroxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Rizatriptan	Rizatriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Rocuronium	The therapeutic efficacy of Rocuronium can be decreased when used in combination with Cisplatin.
Rofecoxib	Rofecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Cisplatin.
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Cisplatin.
Ropeginterferon alfa-2b	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ropivacaine.
Rosiglitazone	Rosiglitazone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Rotavirus vaccine	The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cisplatin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cisplatin.
Ruxolitinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib.
Sacubitril	Sacubitril may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Salbutamol	Salbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Salicylamide	Salicylamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Salicylic acid	Salicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Salmeterol	The risk or severity of hypokalemia can be increased when Cisplatin is combined with Salmeterol.
Salmon calcitonin	Salmon calcitonin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Salsalate	Salsalate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sarilumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Satralizumab.
Saxagliptin	Saxagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Scopolamine	The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin.
Secobarbital	Secobarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Secukinumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab.
Selegiline	The metabolism of Selegiline can be decreased when combined with Cisplatin.
Selenious acid	Selenious acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Selenium	Selenium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Cisplatin.
Sibutramine	Sibutramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Siltuximab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Siltuximab.
Siponimod	The risk or severity of adverse effects can be increased when Cisplatin is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.
Sirolimus	The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirolimus.
Sitagliptin	Sitagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Smallpox (Vaccinia)	The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Cisplatin.
Sodium acetate	Sodium acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sodium aurothiomalate	Sodium aurothiomalate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sodium bisulfite	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Sodium bisulfite.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Cisplatin.
Sodium fluoride	Sodium fluoride may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sodium sulfate	Sodium sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sofosbuvir	Sofosbuvir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Solifenacin	The therapeutic efficacy of Solifenacin can be decreased when used in combination with Cisplatin.
Solriamfetol	Solriamfetol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Cisplatin.
Sorbitol	Sorbitol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sotalol	Cisplatin may increase the bradycardic activities of Sotalol.
Spesolimab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Spesolimab.
Spironolactone	Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Stiripentol	Stiripentol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin.
Streptomycin	Cisplatin may decrease the excretion rate of Streptomycin which could result in a higher serum level.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin.
Strontium chloride	Strontium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Succinylcholine	The metabolism of Succinylcholine can be decreased when combined with Cisplatin.
Sucralfate	Sucralfate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sulbactam	Sulbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sulfadiazine	Sulfadiazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cisplatin.

Zonisamide	Zonisamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Zoledronic acid	The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid.
Ziprasidone	The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Cisplatin.
Zanubrutinib	The metabolism of Zanubrutinib can be decreased when combined with Cisplatin.
Zanamivir	Zanamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Zaleplon	Zaleplon may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cisplatin.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Cisplatin.
Warfarin	Cisplatin may decrease the excretion rate of Warfarin which could result in a higher serum level.
Voxelotor	The metabolism of Voxelotor can be decreased when combined with Cisplatin.
Vortioxetine	Vortioxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Vorinostat	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vorinostat.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Cisplatin.
Voclosporin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Voclosporin.
Vinorelbine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin.
Vincristine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine.
Vinblastine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine.
Viloxazine	Viloxazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Vilanterol	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vilanterol.
Vibrio cholerae	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cisplatin.
Verapamil	Verapamil may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Venlafaxine	Venlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Cisplatin.
Vedolizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Vedolizumab.
Vecuronium	The therapeutic efficacy of Vecuronium can be decreased when used in combination with Cisplatin.
Varicella zoster vaccine	The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Cisplatin.
Varicella zoster vaccine	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cisplatin.
Varenicline	The excretion of Varenicline can be decreased when combined with Cisplatin.
Vandetanib	The serum concentration of Cisplatin can be increased when it is combined with Vandetanib.
Vancomycin	Vancomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Valproic acid	The metabolism of Valproic acid can be decreased when combined with Cisplatin.
Valganciclovir	Valganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Valdecoxib	Valdecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Valbenazine	Valbenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Valaciclovir	Valaciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Vaborbactam	Vaborbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Cisplatin.
Upadacitinib	The risk or severity of adverse effects can be increased when Cisplatin is combined with Upadacitinib.
Umeclidinium	The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Cisplatin.
Typhoid Vi	The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cisplatin.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cisplatin.
Typhoid vaccine	The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cisplatin.
Tucatinib	The serum concentration of Cisplatin can be increased when it is combined with Tucatinib.
Tubocurarine	Cisplatin may increase the neuromuscular blocking activities of Tubocurarine.
Trospium	The therapeutic efficacy of Trospium can be decreased when used in combination with Cisplatin.
Tropisetron	Tropisetron may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Trimetrexate	Trimetrexate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Trimethoprim	The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim.
Trimethaphan	Cisplatin may increase the neuromuscular blocking activities of Trimethaphan.
Trimebutine	Trimebutine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Trilostane	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Trilostane.
Trilaciclib	The risk or severity of nephrotoxicity can be increased when Trilaciclib is combined with Cisplatin.
Trihexyphenidyl	The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Cisplatin.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Cisplatin.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin.
Triflupromazine	The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Cisplatin.
Triethylenetetramine	Triethylenetetramine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Trichlormethiazide	Trichlormethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Triazolam	Triazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Triamterene	Triamterene may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Triamcinolone	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Triamcinolone.
Tretinoin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Tretinoin.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Cisplatin is combined with Trastuzumab emtansine.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Cisplatin.
Trametinib	Trametinib may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tramadol	Tramadol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Trabectedin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Trabectedin.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin.
Torasemide	The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin.
Topotecan	The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan.
Topiramate	Topiramate may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolvaptan	Tolvaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.
Tolterodine	Tolterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolmetin	Tolmetin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolfenamic acid	Tolfenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolcapone	Tolcapone may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolbutamide	Tolbutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tolazamide	Tolazamide may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tofacitinib	Cisplatin may increase the immunosuppressive activities of Tofacitinib.
Tocopherol	Tocopherol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tocilizumab	The risk or severity of adverse effects can be increased when Cisplatin is combined with Tocilizumab.
Tobramycin	Cisplatin may decrease the excretion rate of Tobramycin which could result in a higher serum level.
Tixocortol	The therapeutic efficacy of Cisplatin can be decreased when used in combination with Tixocortol.
Tirofiban	Tirofiban may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tipiracil	The excretion of Tipiracil can be decreased when combined with Cisplatin.
Tiotropium	Tiotropium may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tiopronin	Tiopronin may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Cisplatin.
Tinidazole	Tinidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Timolol	Timolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.
Tiludronic acid	Tiludronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level.

Pregnancy and Lactation

FDA Pregnancy category D

Pregnancy

There is a possibility of birth defects if either the man or woman is using cisplatin at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately.

Breast-feeding

This medication passes into breast milk. Women receiving this medication should not breastfeed.

How should this medicine be used?

Cisplatin injection comes as a solution (liquid) to be injected over 6 to 8 hours intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once every 3 to 4 weeks.

What special precautions should I follow?

Before taking cisplatin,

tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any other medications, or any of the ingredients in cisplatin injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: amphotericin B (Abelcet; AmBisome; Amphotec, Fungizone Intravenous), anticonvulsants such as phenytoin (Dilantin), bumetanide (Bumex), ethacrynic acid (Edecrin), furosemide (Lasix), pyridoxine (Vitamin B-6). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cisplatin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
tell your doctor if you have kidney disease or hearing problems. Your doctor may not want you to receive cisplatin injection.
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving cisplatin. If you become pregnant while receiving cisplatin, call your doctor. Cisplatin may harm the fetus.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breastfeeding, and any other significant facts about your health. These factors may affect how you should use this medication.

Blood clotting: This medication can reduce the number of platelet cells in the blood and increase your risk of bleeding. Tell your doctor immediately if you notice any signs that your blood is not clotting as quickly as usual (e.g., black and tarry stools, blood in the urine, easy bruising, or cuts that won’t stop bleeding). Your doctor will do blood tests regularly to monitor the number of platelets in your blood.

Gout: This medication may cause high levels of uric acid in the blood, making gout more likely to occur. If you have gout or a history of gout, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Report any unusual joint pain or swelling to your doctor as soon as possible.

Hearing impairment: This medication can cause permanent hearing damage and should not be given to anyone with hearing impairment. Your hearing will be monitored closely while you are using this medication.

Infection: In addition to killing cancer cells, this medication can reduce the number of cells that fight infection in the body (white blood cells). If possible, avoid contact with people with contagious infections. Tell your doctor immediately if you notice signs of an infection, such as fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness. Your doctor will do blood tests regularly to monitor the number of specific types of blood cells in your blood.

Kidney function: Cisplatin can reduce kidney function and cause kidney damage. For this reason, it is very important to drink plenty of fluids right after your treatment. Your doctor may want you to drink extra fluids while taking this medication in order to help you pass more fluid and protect your kidneys. Your doctor will monitor your kidney function closely while you are using this medication. If you have reduced kidney function you should not use this medication.

Nervous system: Cisplatin can cause damage to the nervous system. If you experience symptoms such as loss of taste, tingling in the hands or feet, or balance trouble, tell your doctor as soon as possible. These side effects are often reversible if the medication is stopped early.

References

https://www.cancer.gov/about-cancer/treatment/drugs/cisplatin
https://www.ncbi.nlm.nih.gov/books/NBK547695/
https://www.webmd.com/drugs/2/drug-8756/cisplatin-intravenous/details/list-contraindications
https://en.wikipedia.org/wiki/Cisplatin
https://go.drugbank.com/drugs/DB00515
https://medlineplus.gov/druginfo/meds/a684036.html
https://www.drugs.com/mtm/cisplatin.html
ChemIDplus

LICENSE

https://www.nlm.nih.gov/copyright.html

Cisplatin [USAN:USP:INN:BAN:JAN]

https://chem.nlm.nih.gov/chemidplus/sid/0015663271
EPA DSSTox

LICENSE

https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources

Cisplatin

https://comptox.epa.gov/dashboard/DTXSID4024983

CompTox Chemicals Dashboard Chemical Lists

https://comptox.epa.gov/dashboard/chemical-lists/
European Chemicals Agency (ECHA)

https://echa.europa.eu/web/guest/legal-notice

cisplatin

https://echa.europa.eu/substance-information/-/substanceinfo/100.036.106

cisplatin

https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/52479
DailyMed

LICENSE

https://www.nlm.nih.gov/copyright.html

CISPLATIN

https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=CISPLATIN
Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

https://haz-map.com/About

Cisplatin

https://haz-map.com/Agents/1877
International Agency for Research on Cancer (IARC)

https://publications.iarc.fr/Terms-Of-Use

Cisplatin

https://monographs.iarc.who.int/list-of-classifications
LiverTox

LICENSE

https://www.nlm.nih.gov/copyright.html

Cisplatin

https://www.ncbi.nlm.nih.gov/books/n/livertox/Cisplatin/
National Drug Code (NDC) Directory

https://www.fda.gov/about-fda/about-website/website-policies#linking

CISPLATIN

https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory
NCI Cancer Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

Brexucabtagene Autoleucel

https://www.cancer.gov/about-cancer/treatment/drugs/brexucabtageneautoleucel
NCI Investigational Drugs

LICENSE

https://www.cancer.gov/policies/copyright-reuse

CISPLATIN

http://dtp.nci.nih.gov/NCI-InvestigationalDrugsCI92/119875%20(1992).txt
Protein Data Bank in Europe (PDBe)

http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/CPT
WHO Model Lists of Essential Medicines

https://www.who.int/about/who-we-are/publishing-policies/copyright

Cisplatin

https://list.essentialmeds.org/medicines/79
Wikidata

LICENSE

CCZero

https://creativecommons.org/publicdomain/zero/1.0/

Cisplatin

https://www.wikidata.org/wiki/Q412415
Wikipedia

Cisplatin

https://en.wikipedia.org/wiki/Cisplatin
PubChem

https://pubchem.ncbi.nlm.nih.gov

Continue through a complete learning pathway

Move from understanding the topic to symptoms, tests, treatment, medicines, monitoring, and prevention.

Search the complete library

Conditions & Diseases

Background, symptoms, causes, diagnosis, and care.

Explore this library

Tests & Investigations

Laboratory, imaging, screening, and diagnostic education.

Explore this library

Medicines

Uses, safety, monitoring, and related medicine knowledge.

Explore this library

Cancer Knowledge

Cancer types, screening, oncology, and treatment education.

Explore this library

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

Write when the problem started and how it changed.
Bring old prescriptions, investigation reports, and current medicines.
Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

What is the most likely cause of my symptoms?
Which danger signs mean I should go to hospital quickly?
Which tests are necessary now, and which can wait?
How should I take medicines safely and what side effects should I watch for?
When should I come for follow-up?

Tests to discuss

Vital signs: temperature, pulse, blood pressure, oxygen saturation
Basic physical examination by a clinician
CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

Avoid heavy lifting, sudden bending, and prolonged bed rest.
Use comfortable posture and gentle movement as tolerated.
Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

Do not start antibiotics without a proper medical decision.
Do not use steroid tablets or injections casually for quick relief.
Do not delay emergency care because of home remedies.

Get urgent help if

Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.

Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician

Tests to discuss with doctor

Neurological examination for leg power, sensation, reflexes, and straight leg raise
X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms

Questions to ask

What is the most likely cause of my symptoms?
Which warning signs mean I should go to emergency care?
Which tests are really needed now?
Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Go to emergency care if you notice:

Severe or rapidly worsening symptoms
Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration

Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.

Step 1
Check danger signs first

If danger signs are present, seek emergency care and do not wait for online information.
Step 2
Record the symptom story

Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.
Step 3
Visit a qualified clinician

A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.
Step 4
Do only useful tests

Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.
Step 5
Follow up and return early if worse

If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips

Take a written symptom diary and all previous prescriptions/test reports.
Do not hide medicines already taken, even herbal or over-the-counter medicines.
Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

Read, save, and share this guide

Article Summary

Key Takeaways